Table 2.
Immunophenotypic and genetic features of the cases
| Case | Immunohistochemistry | Flow cytometry | Proliferation indexa (%) | Molecular pathology | Cytogenetics | |
|---|---|---|---|---|---|---|
| Karyotype | FISH | |||||
| 1 | CD20+, Cyclin-D1+, CD5-, CD23-, CD10- | CD19+, CD20bright (b)+, CD22+, CD24d+, FMC7+, CD5-/dim (d)+, CD10-, CD23-, kappa+ | 10 | 96,5% homology to IgH V4-b1 gene | 46, XX | t(11;14)(q13;q32) |
| 2 | CD20+, Cyclin-D1+, CD5-, CD23-, CD10- | CD19+, CD20b+, CD22+, CD24+, FMC7+, CD5-/d+, CD23-, CD38+, lambda + (80% of lymphoma cells) kappa + (20% of lymphoma cells) | 10 | 100% homology to IgH V3-21 gene | 47, XY,+3, t(11;14)(q13;q32) | t(11;14)(q13;q32), trisomy 3 |
| 3 | CD20+, Cyclin-D1+, CD5+, CD23-, CD10- | 40 | No material available | Not performed | t(11;14)(q13;q32) | |
| 4 | CD20+, Cyclin-D1+, CD5+, CD23-, CD10- | 20–30 | No material available | Not performed | t(11;14)(q13;q32) | |
| 5 | CD20+, Cyclin-D1+/-, CD5 + (weak), CD23-, CD10- | CD19+, CD20+, CD5+, CD10-, CD23-, lambda+ | 10–20 | 100% homology to IgH V3-21 gene | Failed | t(11;14)(q13;q32) |
| 6 | CD20+, Cyclin-D1+/-, CD5+, CD23-, CD10- | CD19+, CD20b+, CD22+, CD24+, FMC7+, CD5+, CD10-, CD23+, CD38+, kappa+ | 10 | 95,7% homology to IgH V3-7 gene | Failed | t(11;14)(q13;q32) in 13% of cells |
| 7 | CD20+, Cyclin-D1+, CD5+, CD23-, CD10- | 10 | No material available | Not performed | t(11;14)(q13;q32) | |
aEstimated from Ki67 staining